Beta Drugs Limited — Important, 12-11-2024: Agreements

Beta Drugs Limited has executed a Shareholders’ Agreement and a Securities Subscription Agreement with Healthquad Fund II and Inti Capital, alongside its promoters. The Shareholders’ Agreement outlines the governance structure and inter se rights amongst the investors and promoters, ensuring that the management remains with the promoters. The Securities Subscription Agreement details the terms for subscribing to compulsorily convertible debentures and equity shares.

The equity shares will have a face value of INR 10 and a premium of INR 1643.40, while the compulsorily convertible debentures will have a face value of INR 1653.40. The agreements include provisions for appointing a director by Investor 1 and pre-emptive rights for future equity securities issuances.

This strategic tie-up could provide Beta Drugs with additional capital and enhance its governance framework, which may bolster investor confidence and support future growth initiatives. Watch closely for further developments as these agreements are contingent upon regulatory approvals.